S'abonner

ERICVA Risk Scale simplified as a predictor of amputation in critical limb ischemia - 31/08/22

Doi : 10.1016/j.jdmv.2022.07.002 
María Luisa Mantilla Ibañez a, Fernando Sánchez Bardales a, c, Carlos Zavaleta Corvera a, , Jose Caballero Alvarado d, Gabriela Pozzuoli b, Liz Stephanie Muente Alva a
a School of Medicine, Antenor Orrego Private University, Trujillo 13007, Peru 
b La Libertad Healthcare Assistance Network, Essalud, Trujillo 13007, Peru 
c Surgery Department, Alta Complejidad Virgen de la Puerta Hospital, Essalud, Trujillo 13007, Peru 
d Surgery Department, Regional Hospital of Trujillo, Trujillo 13007, Peru 

Corresponding author. Mz T 12 Las Casuarinas, Trujillo 13007, Peru.Mz T 12 Las CasuarinasTrujillo13007Peru

Summary

Objective

Demonstrate that simplified ERICVA (Valladolid Critical Limb Ischaemia Risk Scale) is useful in predicting amputation in chronic limb-threatening ischemia (CLI) after one year of revascularization.

Methods

A retrospective cohort study was performed. We analyzed the medical records of 93 patients over the age of 35 with the diagnosis of CLI who were treated in the Department of Internal Medicine, Orthopedics or in the Cardiovascular Surgery Unit of the Víctor Lazarte Echegaray Hospital and the High Complexity Virgen de La Puerta Hospital during the period 2015-2018. The simplified ERICVA score was determined in patients before surgical and endovascular revascularization. We included 31 patients who scored 2 or more points in the exposed group and 62 patients who scored less than 2 points in the group not exposed to amputation risk. The collected data was analyzed with the statistical program SPSS where the Relative Risk and significance was obtained with Pearson's Chi-square. The multivariate analysis was also carried out in order to obtain the adjusted relative risk.

Results

It was identified that the simplified ERICVA score greater than or equal to 2 points was more frequent in those who underwent amputation (90.3%) compared to patients who did not undergo amputation (4.8%), increasing the risk of amputation in those patients with CLI who underwent revascularization (RR: 18.67, P<0.001). It was also possible to identify that within the group of patients that showed a high risk of amputation according to the ERICVA scale, they had a higher risk of major amputation (RR: 9.32, P<0.001) as opposed to the risk of minor amputation (RR: 1, 89, P=0.193). Among the items of the simplified ERICVA scale, the preoperative neutrophil-lymphocyte ratio and hematocrit were significantly higher in the group of amputated patients (P<0.001). In addition, it was possible to identify that the score greater than or equal to 2 was independently associated with the risk of amputation in patients revascularized with CLI (RR: 13.5, P<0.001).

Conclusion

In our patient population, the simplified ERICVA scale is useful in predicting major and minor amputation in critical limb ischemia after revascularization. The present data showed that the patients who had a simplified ERICVA score greater than or equal to 2 had a higher risk of major amputation compared to the risk of minor amputation. However, it is important to highlight that the impact on the prediction of minor amputation is greater because in some circumstances major amputation can appear as a complication of CLI.

Le texte complet de cet article est disponible en PDF.

Keywords : Peripheral Arterial Disease, Amputation, Critical limb ischaemia, Ericva risk scale


Plan


© 2022  Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 47 - N° 3

P. 116-124 - juillet 2022 Retour au numéro
Article précédent Article précédent
  • The 2022 ITAC evidence-based clinical practice guidelines: New update from the International Initiative on Thrombosis and Cancer to improve the care in patients with cancer-associated thrombosis
  • C. Frere, D. Farge, J. Douketis, J.M. Connors
| Article suivant Article suivant
  • Predicting the risk of recurrent venous thromboembolism: Impact and therapeutic consequences of inherited thrombophilia
  • H. Baccouche, M. Belhadj, F. Said, I. Naceur, A. Chakroun, H. Houman, N. Ben Romdhane

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.